Simulations Plus Inc
NASDAQ:SLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (4), the stock would be worth $26.38 (81% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | $14.56 |
0%
|
| 3-Year Average | 4 | $26.38 |
+81%
|
| 5-Year Average | 4.7 | $30.93 |
+112%
|
| Industry Average | 3.1 | $20.67 |
+42%
|
| Country Average | 2.5 | $16.64 |
+14%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Simulations Plus Inc
NASDAQ:SLP
|
294.2m USD | 2.2 | -4.7 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 20.7 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 8 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26.4B USD | 3.7 | 29 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.5B AUD | 37.2 | 61.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 2.6 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | 26.8 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.9B USD | 1.2 | 42.4 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 4.5 | 18.6 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.3B CNY | 3.4 | -62.7 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 17.2 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
